Deals23 Feb 2026, 09:02 am
Morepen Secures $91M Global CDMO Mandate, Expands Manufacturing Footprint
AI Summary
Morepen Laboratories Limited has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately INR 825 crore (USD 91 million) from a leading global pharma major. The supplies under the mandate are expected to commence within the next 4-5 months. This engagement marks one of the most significant single CDMO mandates in the Company’s history, as it scales its global manufacturing footprint. The mandate reflects the Company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP, and EU approvals.
Key Highlights
- Morepen has secured a $91M CDMO mandate from a leading global pharma major.
- The mandate is expected to commence within the next 4-5 months and continue through Q1 of the following financial year.
- This is one of the most significant single CDMO mandates in Morepen's history, signifying its growing capabilities in regulated markets.
- Morepen's CDMO platform is built on over four decades of API manufacturing expertise and regulatory credibility.
- The Company is evaluating capacity enhancement and technology investments aligned with its expanding CDMO opportunity pipeline.